ymphatic Mapping and Selective (Sentinel) Lymph Node Biopsy for Melanoma Treatment Phase II Study for Therapy of Patients with Early Stage Melanoma
Phase 2
Recruiting
- Conditions
- Early Stage I/II MelanomaCancer - Malignant melanoma
- Registration Number
- ACTRN12605000549628
- Lead Sponsor
- John Wayne Cancer Institute/Royal Adelaide Hospital/University of Adelaide
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Stage I and II cutaneous melanoma > 1mm in Breslow thickness or > Clark Level III; Absence of Metastases; Willingness to attend all scheduled clinical visits, tests and blood sampling.
Exclusion Criteria
Poor performance status; Pregnancy; Other malignancy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie sentinel lymph node biopsy efficacy in early stage melanoma?
How does sentinel lymph node biopsy compare to complete lymph node dissection in melanoma recurrence rates?
Which biomarkers correlate with sentinel lymph node metastasis in stage I/II melanoma patients?
What are the long-term survival outcomes for ACTRN12605000549628 melanoma trial participants?
How do adjuvant therapies impact prognosis after sentinel lymph node biopsy for melanoma?